Clinical trial
Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children With Growth Hormone Deficiency
NCT02339090 is registered in ClinicalTrials.gov with Versartis Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children With Growth Hormone Deficiency
- Lead sponsor
- Versartis Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 26, 2015
- Completion date
- August 23, 2017
- Enrollment
- 138 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.